{"id":"axs-12-reboxetine","safety":{"commonSideEffects":[{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Dry mouth"},{"rate":null,"effect":"Sweating"},{"rate":null,"effect":"Tachycardia"},{"rate":null,"effect":"Urinary retention"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By inhibiting the norepinephrine transporter, reboxetine prevents the reabsorption of norepinephrine from the synaptic cleft, thereby increasing its concentration and duration of action. This mechanism enhances noradrenergic neurotransmission, which is thought to improve mood, attention, and motivation. Reboxetine has minimal effects on serotonin or dopamine reuptake, distinguishing it from other antidepressants.","oneSentence":"Reboxetine is a selective norepinephrine reuptake inhibitor (NRI) that increases norepinephrine levels in the brain by blocking its reuptake at the presynaptic neuron.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:42:19.356Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Major depressive disorder"},{"name":"Attention-deficit/hyperactivity disorder (ADHD)"}]},"trialDetails":[{"nctId":"NCT05113745","phase":"PHASE3","title":"A Study to Assess the Long-term Efficacy and Safety of AXS-12 (Reboxetine) in Subjects With Narcolepsy (ENCORE)","status":"COMPLETED","sponsor":"Axsome Therapeutics, Inc.","startDate":"2021-10-20","conditions":"Narcolepsy, Cataplexy, Excessive Daytime Sleepiness","enrollment":68},{"nctId":"NCT05059223","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of AXS-12 (Reboxetine) in Patients With Narcolepsy","status":"COMPLETED","sponsor":"Axsome Therapeutics, Inc.","startDate":"2021-09-15","conditions":"Narcolepsy, Cataplexy, Excessive Daytime Sleepiness","enrollment":90},{"nctId":"NCT03881852","phase":"PHASE2","title":"Clinical Outcomes in Narcolepsy and Cataplexy: An Evaluation of Reboxetine Treatment (CONCERT)","status":"COMPLETED","sponsor":"Axsome Therapeutics, Inc.","startDate":"2019-01-30","conditions":"Narcolepsy, Cataplexy Narcolepsy, Excessive Sleepiness","enrollment":21}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"AXS-12 (Reboxetine)","genericName":"AXS-12 (Reboxetine)","companyName":"Axsome Therapeutics, Inc.","companyId":"axsome-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Reboxetine is a selective norepinephrine reuptake inhibitor (NRI) that increases norepinephrine levels in the brain by blocking its reuptake at the presynaptic neuron. Used for Major depressive disorder, Attention-deficit/hyperactivity disorder (ADHD).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}